People · Operator
Named in public records as an officer, director or promoter · active 2017–2020 · Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ansun Biopharma, Inc. | — | Pharma | Series C | $195.1M | $3.5B | 2019 |
| Apexigen, Inc. | — | Biotechnology | Series C | $66.4M | $85.6M | 2019 |
| OncoImmune, Inc. | — | Biotechnology | Series A | $8.5M | $108.5M | 2017 |
| Aravive Biologics, Inc. | — | Biotechnology | Pre-Seed | $363K | $20.1M | 2017 |
KAREN LIU at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside KAREN LIU on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Scott Smith | 1 | 16 |
| MICHAEL CHANG | 1 | 13 |
| Gordon Ringold | 1 | 7 |
| George Lee | 1 | 6 |
| Nancy Chang | 1 | 4 |
| Vinay Shah | 1 | 4 |
| William Rutter | 1 | 3 |
| Kenneth Fong | 1 | 3 |
| Yang Liu | 1 | 3 |
| Michael Chao | 1 | 2 |
| Allen Chao | 1 | 2 |
| Martin Devenport | 1 | 2 |
| Amy Wong | 1 | 2 |
| Dan Zabrowski | 1 | 2 |
| Dave Chenn | 1 | 2 |
| Miao Hong | 1 | 2 |
| Herb Cross | 1 | 1 |
| Xiaodong Yang | 1 | 1 |
| Frank Hsu | 1 | 1 |
| MARK ATTEBURY | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.